Do analysts prefer PPCB or BLRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate PPCB or BCLI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, PPCB or BCLI?

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.65 N/A

Is PPCB or BCLI more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% Brainstorm Cell Therapeutics N/A N/A -519.50%

Do analysts prefer PDSB or PPCB?

PDS Biotechnology presently has a consensus target price of $9.00, indicating a potential upside of 3,990.91%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, equities research analysts clearly believe PDS Biotechnology is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PDS Biotechnology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, PDSB or PPCB?

PDS Biotechnology is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PDS Biotechnology N/A N/A -$34.50M -$0.64 N/A Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is PDSB or PPCB more profitable?

Propanc Biopharma's return on equity of -151.28% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -708.18% -136.50% Propanc Biopharma N/A -151.28% -109.53%

Do analysts prefer SNTI or PPCB?

Senti Biosciences presently has a consensus target price of $10.00, suggesting a potential upside of 2,906.61%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Senti Biosciences is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SNTI or PPCB more profitable?

Propanc Biopharma's return on equity of -151.28% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -1,629.80% -119.72% Propanc Biopharma N/A -151.28% -109.53%

Do analysts prefer PPCB or FBLG?

FibroBiologics has a consensus price target of $73.00, indicating a potential upside of 3,933.15%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 FibroBiologics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has higher earnings and valuation, PPCB or FBLG?

FibroBiologics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A FibroBiologics N/A N/A -$18.65M -$5.19 N/A

Is PPCB or FBLG more profitable?

Propanc Biopharma's return on equity of -151.28% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% FibroBiologics N/A -536.78% -225.12%

Propanc Biopharma (PPCB) Competitors

$1.01 -0.01 (-0.98%)

As of 04:00 PM Eastern

Compare

PPCB vs. BLRX, BCLI, PDSB, SNTI, and FBLG

Should you buy Propanc Biopharma stock or one of its competitors? Propanc Biopharma's main competitors and comparable companies include BioLineRx (BLRX), Brainstorm Cell Therapeutics (BCLI), PDS Biotechnology (PDSB), Senti Biosciences (SNTI), and FibroBiologics (FBLG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Propanc Biopharma compare to BioLineRx?

Propanc Biopharma (NASDAQ:PPCB) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioLineRx has higher revenue and earnings than Propanc Biopharma. BioLineRx is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
BioLineRx	$1.18M	9.89	-$1.17M	-$1.69	N/A

Propanc Biopharma has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
BioLineRx	-502.08%	-34.80%	-18.27%

Propanc Biopharma has a beta of 3.52, meaning that its stock price is 252% more volatile than the broader market. Comparatively, BioLineRx has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market.

1.6% of BioLineRx shares are held by institutional investors. 28.7% of Propanc Biopharma shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BioLineRx had 12 more articles in the media than Propanc Biopharma. MarketBeat recorded 12 mentions for BioLineRx and 0 mentions for Propanc Biopharma. BioLineRx's average media sentiment score of 0.08 beat Propanc Biopharma's score of -0.29 indicating that BioLineRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Propanc Biopharma	Neutral
BioLineRx	Neutral

Summary

BioLineRx beats Propanc Biopharma on 8 of the 12 factors compared between the two stocks.

How does Propanc Biopharma compare to Brainstorm Cell Therapeutics?

Propanc Biopharma (NASDAQ:PPCB) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Propanc Biopharma has a beta of 3.52, indicating that its stock price is 252% more volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

In the previous week, Brainstorm Cell Therapeutics had 2 more articles in the media than Propanc Biopharma. MarketBeat recorded 2 mentions for Brainstorm Cell Therapeutics and 0 mentions for Propanc Biopharma. Brainstorm Cell Therapeutics' average media sentiment score of 0.00 beat Propanc Biopharma's score of -0.29 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Propanc Biopharma	Neutral
Brainstorm Cell Therapeutics	Neutral

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 28.7% of Propanc Biopharma shares are owned by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.65	N/A

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

Summary

Brainstorm Cell Therapeutics beats Propanc Biopharma on 6 of the 11 factors compared between the two stocks.

How does Propanc Biopharma compare to PDS Biotechnology?

PDS Biotechnology (NASDAQ:PDSB) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Propanc Biopharma's return on equity of -151.28% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-708.18%	-136.50%
Propanc Biopharma	N/A	-151.28%	-109.53%

PDS Biotechnology has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.52, suggesting that its share price is 252% more volatile than the broader market.

26.8% of PDS Biotechnology shares are held by institutional investors. 8.4% of PDS Biotechnology shares are held by insiders. Comparatively, 28.7% of Propanc Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PDS Biotechnology is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

In the previous week, PDS Biotechnology had 1 more articles in the media than Propanc Biopharma. MarketBeat recorded 1 mentions for PDS Biotechnology and 0 mentions for Propanc Biopharma. PDS Biotechnology's average media sentiment score of 0.71 beat Propanc Biopharma's score of -0.29 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
PDS Biotechnology	Positive
Propanc Biopharma	Neutral

PDS Biotechnology presently has a consensus target price of $9.00, indicating a potential upside of 3,990.91%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, equities research analysts clearly believe PDS Biotechnology is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

PDS Biotechnology beats Propanc Biopharma on 8 of the 13 factors compared between the two stocks.

How does Propanc Biopharma compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

In the previous week, Senti Biosciences' average media sentiment score of 0.00 beat Propanc Biopharma's score of -0.29 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Senti Biosciences	Neutral
Propanc Biopharma	Neutral

Senti Biosciences presently has a consensus target price of $10.00, suggesting a potential upside of 2,906.61%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Senti Biosciences is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Propanc Biopharma's return on equity of -151.28% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-1,629.80%	-119.72%
Propanc Biopharma	N/A	-151.28%	-109.53%

Senti Biosciences has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.52, meaning that its share price is 252% more volatile than the broader market.

Propanc Biopharma has lower revenue, but higher earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	518.02	-$61.44M	-$1.77	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

25.7% of Senti Biosciences shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by insiders. Comparatively, 28.7% of Propanc Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Senti Biosciences beats Propanc Biopharma on 8 of the 14 factors compared between the two stocks.

How does Propanc Biopharma compare to FibroBiologics?

Propanc Biopharma (NASDAQ:PPCB) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, FibroBiologics had 3 more articles in the media than Propanc Biopharma. MarketBeat recorded 3 mentions for FibroBiologics and 0 mentions for Propanc Biopharma. FibroBiologics' average media sentiment score of 0.16 beat Propanc Biopharma's score of -0.29 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Propanc Biopharma	Neutral
FibroBiologics	Neutral

Propanc Biopharma has a beta of 3.52, meaning that its stock price is 252% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Propanc Biopharma's return on equity of -151.28% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
FibroBiologics	N/A	-536.78%	-225.12%

FibroBiologics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

FibroBiologics has a consensus price target of $73.00, indicating a potential upside of 3,933.15%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

FibroBiologics beats Propanc Biopharma on 7 of the 11 factors compared between the two stocks.

Get Propanc Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPCB vs. The Competition

Export

Metric	Propanc Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.32M	$4.03B	$7.28B	$12.92B
Dividend Yield	N/A	3.60%	2.53%	8.90%
P/E Ratio	-0.04	12.65	272.42	25.42
Price / Sales	N/A	1,342.84	623.39	95.06
Price / Cash	N/A	107.40	77.39	52.28
Price / Book	0.03	16.15	12.85	6.17
Net Income	-$58.92M	-$22.76M	$3.47B	$349.50M
7 Day Performance	-25.19%	1.13%	1.24%	-0.05%
1 Month Performance	-0.98%	8.93%	5.81%	0.80%
1 Year Performance	-97.96%	52.96%	25.75%	15.62%

Propanc Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPCB Propanc Biopharma	0.5953 of 5 stars	$1.01 -1.0%	N/A	-98.4%	$2.32M	N/A	N/A	1	Gap Down
BLRX BioLineRx	0.6804 of 5 stars	$2.80 +7.7%	N/A	-25.9%	$12.23M	$1.40M	N/A	40	News Coverage Earnings Report Analyst Revision High Trading Volume
BCLI Brainstorm Cell Therapeutics	N/A	$1.07 -5.2%	N/A	+39.0%	$12.12M	N/A	N/A	40	News Coverage
PDSB PDS Biotechnology	2.6612 of 5 stars	$0.21 +1.5%	$9.00 +4,105.6%	-83.1%	$11.98M	N/A	N/A	20
SNTI Senti Biosciences	2.9034 of 5 stars	$0.38 +0.3%	$10.00 +2,543.4%	-76.4%	$11.78M	$55K	N/A	4	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPCB) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Propanc Biopharma (PPCB) Competitors

PPCB vs. BLRX, BCLI, PDSB, SNTI, and FBLG

How does Propanc Biopharma compare to BioLineRx?

Summary

How does Propanc Biopharma compare to Brainstorm Cell Therapeutics?

Summary

How does Propanc Biopharma compare to PDS Biotechnology?

Summary

How does Propanc Biopharma compare to Senti Biosciences?

Summary

How does Propanc Biopharma compare to FibroBiologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Propanc Biopharma (PPCB) Competitors

PPCB vs. BLRX, BCLI, PDSB, SNTI, and FBLG

How does Propanc Biopharma compare to BioLineRx?

Do analysts prefer PPCB or BLRX?

Which has stronger earnings and valuation, PPCB or BLRX?

Is PPCB or BLRX more profitable?

Which has more risk & volatility, PPCB or BLRX?

Do insiders & institutionals hold more shares of PPCB or BLRX?

Does the media favor PPCB or BLRX?

Summary

How does Propanc Biopharma compare to Brainstorm Cell Therapeutics?

Which has more risk & volatility, PPCB or BCLI?

Does the media prefer PPCB or BCLI?

Do institutionals & insiders believe in PPCB or BCLI?

Do analysts rate PPCB or BCLI?

Which has stronger valuation and earnings, PPCB or BCLI?

Is PPCB or BCLI more profitable?

Summary

How does Propanc Biopharma compare to PDS Biotechnology?

Is PDSB or PPCB more profitable?

Which has more risk & volatility, PDSB or PPCB?

Do institutionals and insiders believe in PDSB or PPCB?

Which has better earnings and valuation, PDSB or PPCB?

Does the media prefer PDSB or PPCB?

Do analysts prefer PDSB or PPCB?

Summary

How does Propanc Biopharma compare to Senti Biosciences?

Does the media refer more to SNTI or PPCB?

Do analysts prefer SNTI or PPCB?

Is SNTI or PPCB more profitable?

Which has more volatility & risk, SNTI or PPCB?

Which has higher valuation and earnings, SNTI or PPCB?

Do institutionals and insiders believe in SNTI or PPCB?

Summary

How does Propanc Biopharma compare to FibroBiologics?

Does the media prefer PPCB or FBLG?

Which has more risk & volatility, PPCB or FBLG?

Is PPCB or FBLG more profitable?

Which has higher earnings and valuation, PPCB or FBLG?

Do analysts prefer PPCB or FBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools